A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 984-993

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus

By  

GERIATRICS & GERONTOLOGY INTERNATIONAL, Vol. 18, Iss. 1, 2018-01 ,pp. : 108-114

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 591-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sodium‐glucose cotransporter‐2 inhibition improves incretin sensitivity of pancreatic β‐cells in people with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 370-377

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 800-804

John Wiley & Sons Inc

Access to resources Recommend Favorite